ECTRIMS 2016: could lipoic acid prevent brain atrophy?

Written by Lauren Pulling

Further research into new multiple sclerosis (MS) treatments has continued to emerge from the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in London, 14–17 September. A research team, based at VA Portland Health Care System and Health & Science University (both Portland, OR, USA), has presented results from a recent early-stage trial and suggest that lipoic acid (LA) is neuroprotective, and could reduce disability and improve quality of life in secondary progressive MS (SPMS). Previous research has indicated that LA supplements could reduce some of the disabling effects of MS. In this...

To view this content, please register now for access

It's completely free